Lyell Immunopharma (NASDAQ:LYEL) Announces Quarterly Earnings Results

Lyell Immunopharma (NASDAQ:LYEL) released its quarterly earnings results on Thursday. The company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.03, reports. Lyell Immunopharma had a negative return on equity of 33.35% and a negative net margin of 389,368.50%. The company had revenue of $0.03 million for the quarter.

Lyell Immunopharma Price Performance

LYEL opened at $1.22 on Friday. Lyell Immunopharma has a 12-month low of $0.85 and a 12-month high of $3.26. The firm has a market capitalization of $312.32 million, a P/E ratio of -1.49 and a beta of -0.47. The stock has a fifty day moving average of $1.23 and a 200-day moving average of $1.71.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. HC Wainwright reaffirmed a “neutral” rating and set a $1.00 target price on shares of Lyell Immunopharma in a research note on Monday, October 28th. Bank of America downgraded shares of Lyell Immunopharma from a “buy” rating to an “underperform” rating and reduced their price objective for the stock from $6.00 to $1.00 in a report on Wednesday, October 30th.

Institutional Investors Weigh In On Lyell Immunopharma

Several institutional investors and hedge funds have recently modified their holdings of LYEL. Price T Rowe Associates Inc. MD lifted its holdings in Lyell Immunopharma by 1.4% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,731,477 shares of the company’s stock worth $15,013,000 after purchasing an additional 92,594 shares during the last quarter. Opaleye Management Inc. bought a new stake in shares of Lyell Immunopharma during the 1st quarter worth $7,482,000. TD Asset Management Inc grew its stake in Lyell Immunopharma by 4.2% in the 2nd quarter. TD Asset Management Inc now owns 1,004,642 shares of the company’s stock valued at $1,457,000 after buying an additional 40,800 shares during the last quarter. Invenomic Capital Management LP grew its position in shares of Lyell Immunopharma by 16.8% in the first quarter. Invenomic Capital Management LP now owns 871,525 shares of the company’s stock valued at $1,944,000 after purchasing an additional 125,110 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its stake in shares of Lyell Immunopharma by 6.1% in the second quarter. Bank of New York Mellon Corp now owns 671,966 shares of the company’s stock worth $974,000 after purchasing an additional 38,487 shares during the period. Institutional investors and hedge funds own 66.05% of the company’s stock.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.